Amgen Inc. is investing $650 million to expand its U.S. manufacturing network, aiming to enhance production of new cancer therapies and create nearly 750 jobs. This growth comes as the biotechnology company faces a class-action lawsuit over a significant tax liability of $10.7 billion. Despite these challenges, Amgen has shown strong stock performance with a 6.1% year-to-date gain and recognition as one of the top large-cap value stocks to consider.
“Amgen · topped · list of the day's best performing Dow Jones Industrial Average components · trading up 0.9%”
“Amgen · registers · year to date gain · 6.1%”
“Amgen Inc. (NASDAQ:AMGN) · is · one of the best large cap value stocks to buy now”
“Tim Anderson · maintained · a Sell rating on Amgen Inc. (NASDAQ:AMGN)”
“Amgen Inc. (NASDAQ:AMGN) · announced · a $650 million expansion of its U.S. manufacturing network”
“Amgen Inc. (NASDAQ:AMGN) · is · a biotechnology company”
“Amgen Inc. (NASDAQ:AMGN) · delivers · new therapies for patients with complex cancers”
“Amgen · jumped · 3.8%”
“Amgen · is · the day's best performing Dow Jones Industrial Average component · trading up 0.9%”
“Amgen · registers · a year to date gain · 6.1%”
“Amgen (AMGN) · is · a Zacks Rank · #3 (Hold)”
“Amgen (AMGN) · has · Most Accurate Estimate · $5.05 a share”
